Vcare PharmaTech Ranked in Tier 1 of "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" for Two Consecutive Years
Published Time:
2026-06-29 17:39
Source:
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
Vcare PharmaTech has secured a spot on the Seed 100 List for six straight years since 2021. It entered Tier 1 for the first time in 2025 and retained this position this year. Its consistent listing and Tier 1 standing serve as high recognition of the company’s long-term dedication to developing innovative medicines and leading therapies, and fully validate its comprehensive strength and steady growth in technological innovation and translation, new drug research as well as clinical development.
AI Empowerment Fuels Differentiated Original Drug Design
Upholding independent incubation and original innovation, Vcare PharmaTech actively integrates cutting-edge technologies with new drug discovery, with a strategic focus on AI-enabled differentiated original molecular design. Artificial intelligence technology accelerates core R&D workflows including target identification, molecular design and candidate compound optimization, greatly boosting R&D efficiency and clinical success rates. This forward-looking strategy has built robust technological barriers across the entire innovative drug development cycle, and further consolidated the deeply collaborative industrial chain covering technology research, drug development and commercial manufacturing.
Accelerated Rollout of Innovation Pipeline; First Anti-Tumor Targeted Drug Granted Marketing Approval
Early June witnessed a landmark breakthrough in Vcare PharmaTech’s innovative drug development pipeline: VELMARTO® (Eratrectinib), the company’s self-developed Class 1 small-molecule targeted anti-tumor drug, obtained marketing approval from the NMPA. This milestone signals Vcare PharmaTech’s official transition from an R&D-focused biotech firm to an integrated enterprise covering both research and commercialization.
Meanwhile, the company’s innovation pipeline has delivered multiple key advances: one candidate drug has formally accepted NDA approval, several candidates are undergoing Phase II and Phase III clinical trials, and a batch of pre-clinical innovative drug programs are under continuous incubation. The tiered pipeline covers core therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, as well as inflammatory and autoimmune disorders, forming a globally competitive product portfolio.
Address Unmet Clinical Needs via Differentiated R&D to Forge Global Competitiveness
Moving forward, Vcare PharmaTech will stay committed to its strategic mission of "addressing unmet clinical needs through differentiated innovation". The company will further expand its innovative drug pipeline, leverage the technical strengths of AI-powered original discovery, and speed up the research, translational development and commercial launch of more Class 1 innovative medicines. It aims to build a diversified innovative drug portfolio with solid technological barriers and outstanding clinical competitiveness across multiple disease areas, deliver superior treatment options for patients worldwide, and fuel high-quality growth of China’s pharmaceutical innovation sector.
About the Seed 100 List
The Seed 100 List selects enterprises representing the innovation potential of China’s pharmaceutical industry. Compiled by authoritative industrial media E Pharma Manager, the ranking adopts an evaluation framework centered on innovation foundation, innovation process and innovation output. Based on Clarivate’s Cortellis competitive intelligence, clinical trial data and Derwent Innovation patent database, evaluators analyze metrics including the number of granted patents, total patent citations, ongoing clinical trial programs, and approved/marketed new medicines to shortlist the top 100 innovative pharmaceutical enterprises.
Previous Page
Related News
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.
View Details
15
2017
/
05
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare on May 12, 2017. The general manager Yongqiang Liu received the delegation.
View Details
24
2017
/
04
Jiangsu Vcare Held Mountain Climbing and Tug-of-war Competitions
Jiangsu Vcare organized mountain climbing and tug-of-war activities recently. The mountain climbing competition was divided into men's and women's groups, and each group competed for top three. The venue was located in Laoshan National Forest Park. Everyone climbed the top after efforts. Four teams consisting of Vcare’s two R&D center members conducted a tug-of-war competition after going down the mountain and finally "Lingya team" won the top spot. Everyone had fun.
View Details
30
2017
/
03
Jiangsu Vcare Held the First Quarter Fire Drill
In order to further improve the safety awareness of new employees, Jiangsu Vcare held a fire-fighting exercise on March 30, 2017. New employees had a deeper understanding of fire extinguishers through on-site explanation of the types, inspection methods and instructions of fire extinguishers. Everyone learned about fire-fighting procedures and the use of appliances. The exercise provided a safety guarantee for everyone’s life and work.
View Details
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
14
2017
/
03
Jiangsu Vcare Held “Firefighting and First Aid” Training
Jiangsu Vcare invited Lei Wang, a special instructor of Nanjing Anqu Fire Education Center to give a “Firefighting and First Aid” course to new employees on March 14, 2017 and 26 new employees participated in the training. Mr. Wang collected a large number of fire cases and carefully analyzed the causes of these fires. He taught everyone how to deal with fires. His explanations made everyone fully aware of the importance and urgency of fire safety. At the same time, everyone had a better understanding of various fire extinguishers and their instructions.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn